In the United States, 1 in 10 adults used GLP-1 class drugs used to treat obesity and diabetes. Nearly half used the drugs in ways that differed from prescriptions, and many cited high prices and supply shortages, raising safety concerns.
IT outlet Ars Technica reported that the U.S. Centers for Disease Control and Prevention (CDC) released results from a survey of 8,118 adults.
Researchers estimated in the July to August survey that 9.8 percent of adults used GLP-1 receptor agonists in the previous 12 months. That is equivalent to about 27 million U.S. adults.
Among 976 GLP-1 drug users, 44 percent said they used the drugs differently from their prescriptions. The most common case was skipping doses, which 28 percent of all users said they had done. Some also delayed refilling prescriptions or reduced their dosage.
Among users who changed how they took the drugs, 38 percent cited cost and 36 percent cited drug supply problems. In the 18 to 39 age group, 58 percent cited cost, higher than those aged 65 and older, at 20 percent.
Use of compounded GLP-1 drugs that do not have formal U.S. Food and Drug Administration (FDA) product approval was also not uncommon. Some 22.6 percent of all users used compounded drugs, and 8.8 percent did not know whether the drug they used was compounded.
Among compounded drug users, 62 percent dosed differently from prescriptions, higher than non-compounded drug users, at 36 percent.
Compounded drugs are made by pharmacies and others to meet a patient's needs. Unlike FDA-approved medicines such as Wegovy and Ozempic, they do not undergo an FDA review of safety, effectiveness and quality for each individual product before sale.
The FDA has warned about dosing calculation errors and manufacturing and contamination problems with compounded GLP-1 drugs. Adverse reactions requiring hospitalisation due to incorrect dosing have also been reported.
Researchers said high drug prices and access problems are affecting how patients take the drugs. They stressed that additional research is needed on safety and treatment effects in real-world use settings.
The survey was based on respondents' self-reports and did not confirm whether prescription changes led to actual side effects or treatment failure.